KR20140012029A - 즉시 사용가능한 케토로락 제제 - Google Patents

즉시 사용가능한 케토로락 제제 Download PDF

Info

Publication number
KR20140012029A
KR20140012029A KR1020137009935A KR20137009935A KR20140012029A KR 20140012029 A KR20140012029 A KR 20140012029A KR 1020137009935 A KR1020137009935 A KR 1020137009935A KR 20137009935 A KR20137009935 A KR 20137009935A KR 20140012029 A KR20140012029 A KR 20140012029A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
ketorolac
pharmaceutically acceptable
acceptable salt
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137009935A
Other languages
English (en)
Korean (ko)
Inventor
조셉 페르골리지
알렉산더 미로노프
차드 제임스 피켄즈
더글라스 자일스 존슨
Original Assignee
알티유 파머수티컬즈, 엘엘시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알티유 파머수티컬즈, 엘엘시 filed Critical 알티유 파머수티컬즈, 엘엘시
Publication of KR20140012029A publication Critical patent/KR20140012029A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020137009935A 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제 Ceased KR20140012029A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40538410P 2010-10-21 2010-10-21
US61/405,384 2010-10-21
US201161481602P 2011-05-02 2011-05-02
US61/481,602 2011-05-02
PCT/US2011/057284 WO2012054831A2 (en) 2010-10-21 2011-10-21 Ready to use ketorolac formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187027505A Division KR102114568B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제

Publications (1)

Publication Number Publication Date
KR20140012029A true KR20140012029A (ko) 2014-01-29

Family

ID=45973506

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020137009935A Ceased KR20140012029A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020187027505A Active KR102114568B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020197019855A Ceased KR20190085561A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020207013936A Active KR102307601B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020187027505A Active KR102114568B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020197019855A Ceased KR20190085561A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020207013936A Active KR102307601B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제

Country Status (19)

Country Link
US (5) US9421191B2 (https=)
EP (3) EP4190327A1 (https=)
JP (1) JP6013346B2 (https=)
KR (4) KR20140012029A (https=)
CN (2) CN108703948A (https=)
CA (1) CA2814805C (https=)
CY (1) CY1122516T1 (https=)
DK (1) DK2616064T3 (https=)
ES (2) ES2753981T3 (https=)
HR (1) HRP20191994T1 (https=)
HU (1) HUE045889T2 (https=)
LT (1) LT2616064T (https=)
MX (1) MX346879B (https=)
PL (1) PL2616064T3 (https=)
PT (1) PT2616064T (https=)
RS (1) RS59526B1 (https=)
SI (1) SI2616064T1 (https=)
SM (1) SMT201900656T1 (https=)
WO (1) WO2012054831A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2616064T (lt) 2010-10-21 2019-11-25 Rtu Pharmaceuticals Llc Parengtos naudoti ketorolako kompozicijos
US10098872B1 (en) 2013-07-22 2018-10-16 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992484B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11559521B2 (en) * 2013-07-22 2023-01-24 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992485B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN103830171B (zh) * 2014-03-04 2015-11-18 鲁南制药集团股份有限公司 一种酮咯酸氨丁三醇注射液及其制备方法
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
MY191574A (en) * 2015-02-10 2022-06-30 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
IT201600075246A1 (it) * 2016-07-19 2018-01-19 Jointherapeutics S R L Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi.
EP4467600A3 (en) * 2017-05-10 2025-03-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
FR3101917B1 (fr) 2019-10-09 2022-07-15 Ifp Energies Now Système de refroidissement à radiateur unique
CN110812325B (zh) * 2019-11-13 2022-04-05 鲁南制药集团股份有限公司 一种提高酮咯酸氨丁三醇注射液存储稳定性的方法
CN119818450A (zh) * 2020-05-19 2025-04-15 南京海融医药科技股份有限公司 一种左酮咯酸的药物组合物及其制备方法
CN114159384B (zh) * 2021-02-07 2023-04-07 南京锐志生物医药有限公司 一种化学性质稳定的低刺激性酮咯酸氨丁三醇注射液
TWI857310B (zh) * 2021-06-24 2024-10-01 大陸商上海雲晟研新生物科技有限公司 酮咯酸胺丁三醇的液體組合物、其製備方法及應用
CN113384524B (zh) * 2021-07-05 2025-08-12 四川尚锐生物医药有限公司 一种稳定的酮咯酸氨丁三醇注射液的制备方法
CN114191384A (zh) * 2021-12-20 2022-03-18 成都倍特药业股份有限公司 一种即用型酮咯酸氨丁三醇和氢溴酸依他佐辛组合液体制剂
CN114432240A (zh) * 2022-03-04 2022-05-06 郑州市中心医院 一种稳定不刺激的酮咯酸氨丁三醇注射液及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US5214052A (en) 1987-07-28 1993-05-25 Mitsubishi Kasei Corporation Method for dissolving arginineamides and pharmaceutical compositions containing them
PT948965E (pt) 1997-07-11 2004-08-31 Toray Industries Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
WO2000057851A2 (en) 1999-03-26 2000-10-05 Pozen Inc. High potency dihydroergotamine compositions
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US20070049552A1 (en) 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20080317681A1 (en) 2003-07-11 2008-12-25 Petros Gebreselassie Compositions containing a stain removing complex, and methods of making and using the same
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
KR20070084211A (ko) * 2004-10-15 2007-08-24 유서홍 약제학적 화합물의 독성을 감소시키기 위한 방법 및 조성물
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
CN101257890B (zh) 2005-09-01 2012-10-31 巴克斯特国际公司 含有酸作为增溶剂的阿加曲班制剂
US20070142478A1 (en) 2005-12-21 2007-06-21 Erning Xia Combination antimicrobial composition and method of use
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
DOP2007000055A (es) * 2006-04-10 2007-10-31 Senosiain S A De C V Lab Composición farmaceutica que comprende un analgésico y vitaminas
MX2008013405A (es) 2006-04-18 2009-03-09 Ekr Therapeutics Inc Composiciones farmaceuticas premezcladas listas para uso.
US20100010046A1 (en) 2006-06-12 2010-01-14 Ironwood Pharmaceuticals, Inc. Pharmaceutical formulation for parenteral administration
JP2009542665A (ja) 2006-06-29 2009-12-03 シェーリング コーポレイション 糖を含まない保存に安定な抗ヒスタミンシロップ
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US20080057023A1 (en) * 2006-08-29 2008-03-06 Chynn Emil W Oxygenated ophthalmic composition
US7589106B2 (en) 2006-09-27 2009-09-15 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
KR100836624B1 (ko) 2006-12-08 2008-06-10 한국전자통신연구원 가변 고속 푸리에 변환 장치 및 그 방법
US20080312154A1 (en) 2007-06-15 2008-12-18 Barbara Lee Peterlin Administration of adipocytokine and adiponectin for treating headache and methods of diagnosing headache by measuring adiponectin
CA2699172C (en) 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
WO2009087658A2 (en) * 2007-11-07 2009-07-16 Sun Pharma Advanced Research Company Limited Composition suitable for parenteral administration
JP5909750B2 (ja) 2007-11-13 2016-04-27 マリンクロット アイピー 低用量静脈内アセトアミノフェン
US20090239836A1 (en) 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US8956636B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
TWI397038B (zh) * 2008-11-05 2013-05-21 Au Optronics Corp 使用半源極驅動架構之顯示面板及其顯示資料供應方法
KR20190031592A (ko) * 2010-07-19 2019-03-26 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
EP2596112A4 (en) 2010-07-21 2015-01-21 Cumberland Pharmaceuticals Inc ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
LT2616064T (lt) 2010-10-21 2019-11-25 Rtu Pharmaceuticals Llc Parengtos naudoti ketorolako kompozicijos

Also Published As

Publication number Publication date
KR20200078541A (ko) 2020-07-01
MX2013004393A (es) 2014-09-12
US9421191B2 (en) 2016-08-23
PT2616064T (pt) 2019-11-06
ES2753981T3 (es) 2020-04-15
SMT201900656T1 (it) 2020-01-14
CA2814805C (en) 2021-11-02
HUE045889T2 (hu) 2020-01-28
WO2012054831A2 (en) 2012-04-26
US20180280351A1 (en) 2018-10-04
US9962371B2 (en) 2018-05-08
EP4190327A1 (en) 2023-06-07
CN103167800A (zh) 2013-06-19
US11116750B2 (en) 2021-09-14
JP2013543843A (ja) 2013-12-09
KR102307601B1 (ko) 2021-09-30
ES2933198T3 (es) 2023-02-02
CA2814805A1 (en) 2012-04-26
KR20190085561A (ko) 2019-07-18
HRP20191994T1 (hr) 2020-02-07
EP3632432A1 (en) 2020-04-08
KR20180119610A (ko) 2018-11-02
WO2012054831A3 (en) 2012-06-07
JP6013346B2 (ja) 2016-10-25
EP2616064B1 (en) 2019-08-07
RS59526B1 (sr) 2019-12-31
CN108703948A (zh) 2018-10-26
EP2616064A4 (en) 2016-07-20
US20190105301A1 (en) 2019-04-11
MX346879B (es) 2017-04-03
PL2616064T3 (pl) 2020-02-28
DK2616064T3 (da) 2019-11-11
SI2616064T1 (sl) 2019-12-31
CY1122516T1 (el) 2021-01-27
US20120101142A1 (en) 2012-04-26
US20170007575A1 (en) 2017-01-12
EP3632432B1 (en) 2022-09-14
EP2616064A2 (en) 2013-07-24
US20220023260A1 (en) 2022-01-27
US10278959B2 (en) 2019-05-07
KR102114568B1 (ko) 2020-05-22
LT2616064T (lt) 2019-11-25

Similar Documents

Publication Publication Date Title
KR102114568B1 (ko) 즉시 사용가능한 케토로락 제제
CA2923811C (en) Sublingual buprenorphine spray
US10517864B2 (en) Sustained-release buprenorphine solutions
EP2683361B1 (en) Method for the preparaton of a levothyroxine solution
KR20220015456A (ko) 안정한 ast-3424 주사액 제제 및 이의 제조 방법
CA2677281A1 (en) Transoral dosage forms comprising sufentanil and naloxone
US9839611B2 (en) Sublingual buprenorphine spray
WO2024227895A2 (en) Oral solution comprising liothyronine sodium
HK40026993A (en) Ready to use ketorolac formulations
HK40026993B (en) Ready to use ketorolac formulations
JP6081240B2 (ja) レミフェンタニル注射液剤
HK1262803A1 (en) Ready to use ketorolac formulations
WO2014083071A1 (en) Injectable liquid formulation of the combination of tramadol and paracetamol
KR20130070556A (ko) 유기용매 무함유 젬시타빈 수용액 조성물
WO2017091165A1 (en) Liquid formulation of levodropropizine and method for preparation thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130419

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161014

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170912

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180330

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170912

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180330

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180111

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20161014

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180628

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180501

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180330

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180111

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170912

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20161014

X601 Decision of rejection after re-examination
A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180921

PJ0201 Trial against decision of rejection

Patent event date: 20180921

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20180628

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20180330

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20181106

Appeal identifier: 2018101003943

Request date: 20180921

J801 Dismissal of trial

Free format text: TRIAL NUMBER: 2018101003943; REJECTION OF TRIAL FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180921

Effective date: 20181106

PJ0801 Rejection of trial

Patent event date: 20181106

Patent event code: PJ08011S01D

Comment text: Decision on Dismissal of Request for Trial (Dismissal of Decision)

Decision date: 20181106

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2018101003943

Request date: 20180921